Niagen Bioscience, Inc. (NAGE) - Total Liabilities
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has total liabilities worth $27.46 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NAGE working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Niagen Bioscience, Inc. - Total Liabilities Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Niagen Bioscience, Inc..
Niagen Bioscience, Inc. Competitors by Total Liabilities
The table below lists competitors of Niagen Bioscience, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acadian Timber Corp
TO:ADN
|
Canada | CA$280.19 Million |
|
Shanghai Jin Jiang International Hotels Development Co Ltd B
SHG:900934
|
China | $30.00 Billion |
|
Omaxe Limited
NSE:OMAXE
|
India | Rs174.15 Billion |
|
ICP DAS Co Ltd
TWO:3577
|
Taiwan | NT$367.73 Million |
|
First Savings Financial Group Inc
NASDAQ:FSFG
|
USA | $2.21 Billion |
|
Sichuan Dowell Science and Technology Inc
SHE:300535
|
China | CN¥546.93 Million |
|
Activate Energy Acquisition Corp. Class A Ordinary Share
NASDAQ:AEAQ
|
USA | $8.24 Million |
|
Hansae Co
KO:105630
|
Korea | ₩855.67 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Niagen Bioscience, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NAGE net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Niagen Bioscience, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual total liabilities of Niagen Bioscience, Inc. from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.18 Million | -16.31% |
| 2023-12-31 | $26.51 Million | +4.42% |
| 2022-12-31 | $25.39 Million | -2.79% |
| 2021-12-31 | $26.11 Million | +19.05% |
| 2020-12-31 | $21.93 Million | +10.77% |
| 2019-12-31 | $19.80 Million | +31.54% |
| 2018-12-31 | $15.05 Million | +69.34% |
| 2017-12-31 | $8.89 Million | -9.08% |
| 2016-12-31 | $9.78 Million | -27.44% |
| 2015-12-31 | $13.47 Million | +79.22% |
| 2014-12-31 | $7.52 Million | +126.36% |
| 2013-12-31 | $3.32 Million | -34.11% |
| 2012-12-31 | $5.04 Million | +35.93% |
| 2011-12-31 | $3.71 Million | +136.04% |
| 2010-12-31 | $1.57 Million | -37.59% |
| 2009-12-31 | $2.52 Million | +7.87% |
| 2008-12-31 | $2.33 Million | +583386.75% |
| 2007-12-31 | $400.00 | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more